InvestorsObserver
Sign Up Login

SNOA Sonoma Pharmaceuticals Inc.

$0.16 $0.00 (-0.63%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

SNOA Stock Analysis Overview

What this means: InvestorsObserver gives Sonoma Pharmaceuticals Inc. (SNOA) an overall rank of 33, which is below average. Sonoma Pharmaceuticals Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

SNOA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

SNOA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

SNOA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

SNOA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

SNOA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

SNOA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

SNOA Stock Analysis Overview

What this means: InvestorsObserver gives Sonoma Pharmaceuticals Inc. (SNOA) an overall rank of 33, which is below average. Sonoma Pharmaceuticals Inc. is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full SNOA report

SNOA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

SNOA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

SNOA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

SNOA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

SNOA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

SNOA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Sonoma Pharmaceuticals Inc. (SNOA) Analyst Forecast

SNOA Price, Volume, Earnings, and Dividend Date

  • Last Price $0.16
  • Previous Close $0.16
  • Change $0.00
  • Open $0.16
  • Volume 150,287
  • Avg. Volume (100-day) 1,802,990
  • Market Cap 2,481,582
  • Days Range 0.1505 - 0.1599
  • 52-week Range 0.12 - 1.52
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 05/08/24
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 0.328
  • PEG Ratio —

Sonoma Pharmaceuticals Inc. (SNOA) Company Description

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.

Sonoma Pharmaceuticals Inc. (SNOA) Stock Chart

View Interactive SNOA chart

My Watchlists

Top Stocks in Drug Manufacturers - Specialty & Generic